Alexion Pharma

Wilson Therapeutics is a biopharmaceutical company based in Stockholm, Sweden, that develops novel therapies for rare diseases. The company is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX. As of 2016, tetrathiomolybdate had been tested in over 500 patients for up to seven years, primarily in oncology and Wilson's disease, as well as some other clinical pathologies.

Wilson Therapeutics

Synageva was a publicly listed biopharmaceutical company headquartered in Lexington, Massachusetts dedicated to discovering, developing and delivering medicines for patients with rare diseases and high unmet medical needs. The company had manufacturing and laboratory locations in Lexington and Holden, Massachusetts, Bogart and Athens Georgia, as well as offices in a variety of locations around the world.

Synageva

Alexion Pharmaceuticals is a biopharmaceutical company, which is engaged in the discovery, development, and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney and neurologic diseases, transplant rejection, cancer, and autoimmune disorders. Its marketed product Soliris (eculizumab) is a therapy approved for the treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH).  In April 2009 and August 2009, the United States food and drug administration (FDA) and the European Commission (E.C.), respectively, granted Soliris orphan drug designation for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). In December 2009, its Rhode Island manufacturing facility received regulatory approval from the E.C. Or the production of Soliris.

Boise Cascade

Ford Motor Company

General Motors

Group 1 Automotive

Envista Holdings Corp

Vale S.A.

P/B ratio is emerging as a convenient tool to identify low-priced stocks that have high-growth prospects.

7 Low Price-to-Book Stocks Worth Buying in July

Broadcom

AstraZeneca

These stocks offer the best of both worlds: rapid sales growth and a market-topping dividend yield.

3 of the Fastest-Growing Dividend Stocks on the Planet

AstraZeneca (AZN) obtains European Commission's permission for the acquisition of Alexion. The deal is expected to close in the third quarter of 2021.

AstraZeneca (AZN) Gets EC's Clearance for Alexion Acquisition

AstraZeneca PLC (LON:AZN) announced it has received EU approval for the US$39bn (£27.5bn) acquisition of Alexion Pharmaceuticals, Inc., expected to complete in the third quarter. The pharma giant has already received approval in the US, Canada, Brazil, Russia and Japan but is still waiting for the green light from the UK.

AstraZeneca receives EU clearance for £27.5bn Alexion acquisition

Genmab - ADR

ALXN vs. GMAB: Which Stock Is the Better Value Option?

ALXN or GMAB: Which Is the Better Value Stock Right Now?

BORDENTOWN, N.J. & BOSTON--(BUSINESS WIRE)--Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the EHA Congress 2021

Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021

The FDA approves Alexion's (ALXN) Ultomiris for the treatment of PNH in children of one month of age and older as well as adolescents.

Alexion's (ALXN) PNH Drug Ultomiris Gets FDA Nod for Kids

BOSTON--(BUSINESS WIRE)--Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)

EU antitrust regulators will decide by July 5 whether to clear Anglo-Swedish drugmaker AstraZeneca's $39 billion bid for U.S.-based Alexion, a European Commission filing showed on Tuesday.

EU to decide on Astrazeneca's $39 billion Alexion deal by July 5

AstraZeneca PLC (LON:AZN) announced it has priced €800mln (£691mln) of fixed-rate notes related to the proposed acquisition of Alexion Pharmaceuticals, Inc. They have a coupon of 0.375% maturing in 2029, but must be redeemed before the maturity date if the deal doesn't happen before 12 March 2022 or if it gets scrapped.

AstraZeneca prices £691mln bond offering linked to Alexion Pharmaceuticals, Inc. acquisition

The U.K. competition regulator is mulling over AstraZeneca Plc's (NASDAQ: AZN) $39 billion takeover taker of Alexion Pharmaceuticals Inc (NASDAQ: ALXN) over competition concern. The U.K.'s Competition and Markets Authority is starting the first phase of the probe today and said it should wrap it up by 21 July, deciding at that point whether to start a second, more in-depth appraisal of the deal.

UK Competition Watchdog Probes AstraZeneca's $39B Alexion Takeover

The deal, which would be financed by a $25 billion capital increase once it is concluded, was approved by AstraZeneca shareholders two weeks ago.

U.K. Watchdog to Investigate AstraZeneca's $39 Billion Alexion Takeover

The deal has already been approved by the U.S. and Canadian authorities.

AstraZeneca's $39 billion takeover of U.S.-based Alexion Pharmaceuticals examined by U.K. regulator

AstraZeneca PLC's (LON:AZN) proposed US$39bn (£27.5bn) acquisition of Alexion Pharmaceuticals, Inc. is now under investigation by the Competition and Markets Authority (CMA).

AstraZeneca £27.5bn acquisition of Alexion under investigation by competition watchdog

Britain's competition regulator said on Tuesday it was probing if AstraZeneca's $39 billion takeover of U.S. drugmaker Alexion could reduce competition for products and services in the country or elsewhere.

Britain looking into AstraZeneca-Alexion deal for competition concerns

BORDENTOWN, N.J. & BOSTON--(BUSINESS WIRE)--Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021

Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021

BOSTON--(BUSINESS WIRE)--Alexion announces upcoming data presentations at the 26th European Hematology Association virtual Congress

Alexion Announces Upcoming Data Presentations at the 26th European Hematology Association Virtual Congress

BOSTON--(BUSINESS WIRE)--Alexion Shareholders Approve Acquisition by AstraZeneca

Alexion Shareholders Approve Acquisition by AstraZeneca

Applied Materials

Air Products and Chemicals

First Republic

Regions Financial

Elfun Trusts (Trades, Portfolio), part of Boston-based State Street Global Advisors, disclosed this week that its top five trades during the first quarter included a new position in Regions Financial Corp. ( RF , Financial), a boost to its Air Products & Chemicals Inc. ( APD , Financial) holding, the closure of its Alexion Pharmaceuticals Inc. ( ALXN , Financial) holding and reduced positions in Applied Materials Inc. ( AMAT , Financial) and First Republic Bank ( FRC , Financial).

Elfun Trusts' Top 5 Trades of the 1st Quarter

Alexion (ALXN) delivered earnings and revenue surprises of 14.29% and 4.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Alexion Pharmaceuticals (ALXN) Beats Q1 Earnings and Revenue Estimates

Alexion (ALXN) tops earnings and sales in the first quarter of 2021. Its merger with AstraZeneca is expected to close in the third quarter.

Alexion (ALXN) Tops Q1 Earnings, Merger With AstraZeneca On Track

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) moved higher by 2.2% in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 9.32% year over year to $3.52, which beat the estimate of $3.16.

Recap: Alexion Pharmaceuticals Q1 Earnings

BOSTON--(BUSINESS WIRE)--Alexion Reports First Quarter 2021 Results

Alexion Reports First Quarter 2021 Results

Alexion Pharmaceuticals (NASDAQ:ALXN) unveils its next round of earnings this Friday, April 30. Here is Benzinga's everything-that-matters guide for the earnings announcement.

Earnings Outlook For Alexion Pharmaceuticals

BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2021 before the US financial markets open on April 30, 2021, rather than on May 3, 2021 as previously announced. Given the previously announced agreement to be acquired by AstraZeneca, Alexion will not be hosting a conference call. Earnings materials will be made available publicly on the Investor Relations page of our web

News for Alexion Pharma Stock (ALXN)